Provided by Tiger Trade Technology Pte. Ltd.

Tarsus Pharmaceuticals, Inc.

79.31
-1.8100-2.23%
Post-market: 79.310.00000.00%19:30 EDT
Volume:490.79K
Turnover:39.24M
Market Cap:3.48B
PE:-73.27
High:83.23
Open:82.27
Low:79.18
Close:81.12
52wk High:91.53
52wk Low:48.20
Shares:43.88M
Float Shares:32.68M
Volume Ratio:0.48
T/O Rate:1.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0824
EPS(LYR):-1.5900
ROE:-13.68%
ROA:-5.48%
PB:10.04
PE(LYR):-49.88

Loading ...

Tarsus Pharmaceuticals Stockholders Approve Governance and Oversight

TIPRANKS
·
Jun 30

Tarsus Pharmaceuticals Holds Annual Shareholder Meeting

Reuters
·
Jun 30

Tarsus Pharma CEO and Chair Bobak R. Azamian disposes of common shares worth $616,864.54

Reuters
·
Jun 23

Tarsus Pharma Director William J. Link reports $777,809 common share disposal

Reuters
·
Jun 18

Achieve Life Sciences adds Jeffrey Farrow, Reid Waldman to board

Reuters
·
Jun 02

Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, Md to Board of Directors

THOMSON REUTERS
·
Jun 02

Evaluating Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness

Simply Wall St.
·
Jun 02

Tarsus to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 29

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 27

Tarsus Pharmaceuticals (TARS) Gets a Buy from H.C. Wainwright

TIPRANKS
·
May 27

Assessing Tarsus Pharmaceuticals (TARS) Valuation After New TP-05 Phase 2b Lyme Disease Trial Update

Simply Wall St.
·
May 22

Tarsus Advances TP-05 Lyme Prevention Trial, Setting Up a New Mid-Stage Catalyst for TARS Investors

TIPRANKS
·
May 21

Tarsus and John Cena Partner to Raise Awareness of Demodex Blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

THOMSON REUTERS
·
May 14

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

GlobeNewswire
·
May 14

Mizuho Securities Remains a Buy on Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
May 08

Tarsus Pharmaceuticals (TARS) Gets a Buy from Guggenheim

TIPRANKS
·
May 08

Tarsus Pharmaceuticals (TARS) Losses Narrow In Q1 2026 Challenging Bearish Narratives

Simply Wall St.
·
May 08

Tarsus to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 08

Tarsus Pharmaceuticals Earnings Call Signals Durable Growth

TIPRANKS
·
May 07

Tarsus Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07